Cariprazine 1.5 mg Adjunct Beats Placebo in Inadequate-Response Depression
This fixed-dose phase 3 trial adds a second positive adjunctive cariprazine study in major depressive disorder and clarifies that the 1.5 mg dose, not 3 mg, met the multiplicity-adjusted primary endpoint.
Cariprazine 1.5 mg/day shows promise for unmet depression needs.
Many patients with major depressive disorder (MDD) do not respond to antidepressants alone, necessitating effective adjunctive treatment options. Cariprazine 1.5 mg/day significantly improved depression scores compared to placebo and showed greater response rates at week 6. Cariprazine at 1.5 mg/day is effective as an adjunct for MDD, but 3 mg/day did not achieve significance. Safety was consistent with other uses. Cariprazine 1.5 mg/day is effective and well-tolerated for adjunctive MDD treatment.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Sachs GS, Yeung PP, Rekeda L, Khan A, Adams JL, Fava M
Citation:Sachs GS, Yeung PP, Rekeda L, et al. Cariprazine for the Adjunctive Treatment of Major Depressive Disorder: Results of a Randomized Phase 3 Placebo-Controlled Study (Study 301). CNS spectrums. 2023;28(2):254-255. doi:10.1017/S1092852923001980